UK markets closed

Hutchison China MediTech Limited (HCM.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
252.00+10.00 (+4.13%)
At close: 05:05PM BST
Full screen
Previous close242.00
Bid252.50 x 0
Ask257.00 x 0
Day's range220.00 - 260.00
52-week range137.80 - 633.00
Avg. volume234,631
Market cap2.179B
Beta (5Y monthly)0.71
PE ratio (TTM)N/A
EPS (TTM)-20.10
Earnings date01 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.16
  • Globe Newswire

    HUTCHMED to Announce 2022 Half-Year Financial Results

    HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2022 on Monday, August 1, 2022 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED managemen

  • Stockopedia

    Which way now for the HUTCHMED (China) share price?

    Geopolitical and economic turmoil has changed the outlook for companies across all industry sectors. For investors who own shares in them, the question now is...

  • Globe Newswire

    HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China

    HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that TAZVERIK® (tazemetostat) has been approved by the Health Commission and Medical Products Administration of Hainan Province to be used in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (“Hainan Pilot Zone”), under the Clinically Urgently Needed Imported Drugs scheme, for the treatment of certain patients wi